LONDON, ONTARIO--(Marketwire - November 13, 2008) - Stellar Pharmaceuticals Inc. (“Stellar” or the “Company”) (OTCBB: SLXCF) today announced that for the three month period ended September 30, 2008, total product revenues increased by 19.6% compared to the same period in 2007. Product sales in Canada grew by 8.3% and international product sales were up 96.6% due to increased sales of NeoVisc® in Europe. For the nine month period ended September 30, 2008, product revenues increased by 21.6% over the same period in 2007, with Canadian product sales up 3.7% while international sales grew by 139.8% again due to solid growth of NeoVisc in Europe.
